1. Home
  2. AXR vs GNLX Comparison

AXR vs GNLX Comparison

Compare AXR & GNLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo AMREP Corporation

AXR

AMREP Corporation

HOLD

Current Price

$25.21

Market Cap

133.1M

Sector

Real Estate

ML Signal

HOLD

Logo Genelux Corporation

GNLX

Genelux Corporation

HOLD

Current Price

$2.88

Market Cap

132.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AXR
GNLX
Founded
1961
2001
Country
United States
United States
Employees
N/A
N/A
Industry
Homebuilding
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
133.1M
132.7M
IPO Year
2010
2022

Fundamental Metrics

Financial Performance
Metric
AXR
GNLX
Price
$25.21
$2.88
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
4
Target Price
$30.00
$17.25
AVG Volume (30 Days)
11.7K
135.6K
Earning Date
03-12-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
89.60
9.47
EPS
1.68
N/A
Revenue
$12,831,000.00
$8,000.00
Revenue This Year
$10.12
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$14.74
N/A
Revenue Growth
N/A
N/A
52 Week Low
$17.61
$2.29
52 Week High
$29.01
$8.54

Technical Indicators

Market Signals
Indicator
AXR
GNLX
Relative Strength Index (RSI) 42.30 45.57
Support Level $24.25 $2.33
Resistance Level $28.84 $2.97
Average True Range (ATR) 0.75 0.17
MACD -0.09 -0.02
Stochastic Oscillator 5.25 35.42

Price Performance

Historical Comparison
AXR
GNLX

About AXR AMREP Corporation

Amrep Corp through its subsidiaries is engaged in the Real estate business. Its activities include land sales and lease activities, which involve obtaining approvals and selling both developed and undeveloped lots to homebuilders, commercial users, and others, as well as investments in commercial and investment properties. The Company accounts for land sales, home sales, and other revenues. Its operating segments include Land development and Homebuilding. The firm generates a majority of its revenue from the Land development segment. Geographically, all the activities are carried out throughout the United States.

About GNLX Genelux Corporation

Genelux Corp is a late-stage biopharmaceutical firm focused on developing oncolytic viral immunotherapies for cancer. Its pipeline includes clinical and preclinical candidates designed to target tumor cells and stimulate an immune response against tumor-specific antigens. The company is focused on the development of next-generation oncolytic viral immunotherapies that are designed to generate a personalized multi-prong attack to overwhelm a tumor's sophisticated defense mechanisms.

Share on Social Networks: